NCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Institut Paoli-Calmettes
Washington University School of Medicine
University of California, Irvine
OnKure, Inc.
The Netherlands Cancer Institute